Navigation Links
ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
Date:1/18/2008

healthy tissues."

Svein Mathisen, CEO of BioInvent, added: "We are pleased that we and our partner ThromboGenics have taken this innovative anti-cancer agent to the clinical stage. TB-403 could be a novel treatment of cancer. There is a clear medical need for an effective and safe new anti-angiogenic treatment of cancer. TB-403 does not induce an angiogenic switch and resistance to the drug, has potentially less side effects and may therefore be well suited for long term treatment."

ThromboGenics and BioInvent also intend to develop TB-403 for eye diseases, to block uncontrolled blood vessel growth in conditions such as age-related macular degeneration (AMD) and diabetic retinopathy.

Angiogenesis inhibitors such as TB-403 are therapeutic agents that work by blocking the development of new blood vessels, thereby depriving growing cancer tumour cells of oxygen and nutriments. This approach in turn is thought to stop the tumour from growing and spreading to other parts of the body. Currently available angiogenesis inhibitors specifically target vascular endothelial growth factor (VEGF), which plays an important role in promoting the formation of blood vessels. PlGF is a homologue of VEGF but, unlike other angiogenesis factors such as VEGF, it does not affect normal, physiological angiogenesis and is only involved in the angiogenesis process which takes place in the diseased tissue. Therefore, as an inhibitor of PlGF, TB-403 is likely to inhibit tumour growth without the side effects associated with other anti-angiogenic therapies.

Extensive research in this area was recently published as the featured article in the journal Cell ("Anti-PlGF Inhibits Growth of VEGF(R)-Inhibitor-Resistant Tumors Without Affecting Healthy Vessels," Carmeliet, Fischer, et al, Cell 131, 463-475, November 2, 2007).

About ThromboGenics

ThromboGenics is a biotechnology company focused on discovery and development of biopharmaceuticals for the treatment
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
2. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
3. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
4. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
5. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
6. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
7. Biosensors Receives CE Mark Approval for Its BioMatrix(R) Drug-Eluting Coronary Stent System
8. Agennix Receives Special Protocol Assessment Approval from FDA for the Pivotal Trial of Talactoferrin Alfa in First-Line Non-Small Cell Lung Cancer
9. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
10. Genta Receives Notice of Non-Compliance With NASDAQ Rule
11. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 22, 2014   Synthetic Biologics, Inc. (NYSE ... for serious infections and diseases, announced today that the ... of Allowance for a composition of matter patent application ... program, SYN-004. This is Synthetic Biologics, first allowed ... and adds to the Company,s extensive C. difficile ...
(Date:10/22/2014)... KONG , Oct. 22, 2014  aTyr Pharma ... that rare disease expert John C. McKew , ... McKew brings more than two decades of expertise in ... Institutes of Health, Wyeth Research and Genetics Institute, Inc. ... aTyr,s efforts to expand and translate its novel Physiocrine ...
(Date:10/20/2014)... MENLO PARK, Calif. , Oct. 20, 2014 ... announced today that the Company has signed a ... Institute of Regenerative Medicine (CIRM), effective October 1, ... of Clinical Development payments and the release of ... $14.3 million CIRM grant award for clinical development ...
(Date:10/20/2014)... PureTech , a science and ... problems, announced today the closing of a $55 ... Invesco Perpetual, a $120 Billion group of funds. ... existing pipeline forward and to advance new healthcare ... creativity to really go for the big ideas ...
Breaking Biology Technology:Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6
... , , , , , ... , , , , General ... set a, suitable plating protocol for optimal cell density from the beginning to, ... , Dividing versus Non-dividing Cells , Dividing cells ...
... , , , , , ... rapid and highly accurate identification of SNP loci. Our SeeSNP service ... fueled by our capacity , to sequence over 20 million ... facility apart include: , , ...
... , , , CleanSEQ is a SPRI-based dye-terminator ... centrifugation , or filtration steps. CleanSEQ produces superior quality sequencing ... dye-terminator removal , method in many of the top genomic ... HIGH QUALITY SEQUENCING RESULTS , , ...
Cached Biology Technology:General Considerations for Successful Transfection Experiments 2SEESNP DISCOVERY 2
(Date:10/15/2014)... Geneticist Fred Alt will be awarded the 44th Rosenstiel ... University for his pioneering research exploring the mechanisms of ... and cancer cells. Alt is the second alumnus to ... the Nobel Prize in 2003. , Alt is the ... Genetics at Harvard Medical School and an investigator at ...
(Date:10/14/2014)... years since T. rex took its last ... is breathing life back into dinosaurs using high-powered computer ... has important implications for how dinosaurs used their noses ... of smell and cool their brains. , "Dinosaurs ... Jason Bourke, lead author of the new study published ...
(Date:10/14/2014)... Montreal, October 14, 2014 – High doses of fish oil ... fibrillation, a common type of irregular heartbeat in which the ... The results of the AFFORD trial led by the Montreal ... American College of Cardiology on October 7th. , For ... antiarrhythmic therapy were randomly assigned to 4 grams of fish ...
Breaking Biology News(10 mins):Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 3
... three-dimensional plasmon rulers, capable of measuring nanometer-scale spatial ... researchers with the U.S. Department of Energy (DOE),s ... with researchers at the University of Stuttgart, Germany. ... unprecedented details on such critical dynamic events in ...
... awarded the University of Colorado Boulder a six-year, ... long-term ecological changes in Colorado,s high mountains, both ... Awarded to CU-Boulder,s Institute of Arctic and Alpine ... students, including undergraduates, to continue key environmental studies ...
... upon previous efforts producing a high-quality de ... E. coli O104:H4 outbreak ... their collaborators at the University Medical Centre ... map of the genome and plasmids without ...
Cached Biology News:Taking the 3-D measure of macromolecules: 2Taking the 3-D measure of macromolecules: 3NSF awards CU-Boulder $5.9 million grant for alpine ecosystem research 2NSF awards CU-Boulder $5.9 million grant for alpine ecosystem research 3NSF awards CU-Boulder $5.9 million grant for alpine ecosystem research 4The complete map of the Germany E. coli O104 genome released 2
supplied with 10x reaction buffer...
... PBL's bioassays for interferons are cytopathic effect ... assays. Sample types include; tissue culture supernatents; ... In these assays, one unit is defined as ... reduce the cytopathic effect of viral infection by ...
... BioPrime Plus Array CGH Genomic Labeling Systems ... reproducible labeling of genomic DNA samples for ... both indirect and direct labeling formats, the ... provide a flexible solution to your genomic ...
... interferons are cytopathic effect inhibition assays, also known ... include; tissue culture supernatents; serum from PK studies ... unit is defined as the quantity of interferon ... of viral infection by 50%. All ...
Biology Products: